HIF-1α、VEGF在乳腺癌中的表达及其与化疗敏感性的关系

Expressions of HIF-1α,VEGF and the relationship with chemosensitivity in breast carcinoma

目的探讨HIF-1α、VEGF在乳腺癌中的表达及其与新辅助化疗敏感性的关系。方法应用免疫组织化学S-P法检测52例乳腺癌患者新辅助化疗前、后瘤体组织HIF-1α、VEGF的表达,评估其与化疗疗效的关系。结果化疗前乳腺癌HIF-1α阳性表达为46.15%,化疗后降到21.15%,差异有统计学意义(P<0.05);VEGF的表达化疗前为55.77%,化疗后降到30.77%,差异有统计学意义(P<0.05)。化疗前后HIF-1α的表达与VEGF正相关,P<0.05。新辅助化疗前HIF-1α和VEGF表达阳性者均较阴性者化疗敏感性差,P<0.05。结论 HIF-1α和VEGF可作为乳腺癌化疗敏感性的预测因子,有助于制定个体化化疗方案。

Objective To study the expressions of Hypoxia-inducible factor la （HIFla）, Vascular endothelial growth factor（VEGF） and the relationship with chemosensitivity in breast carcinoma. Methods Immunohistochemical UltraSensitiveTM S-P method was used to detect differences in tumor tissue HIF-1α, VEGF expression and the situation before and after chemotherapy in 52 cases of breast cancer to neoadjuvant chemotherapy. Results Before and after chemotherapy, the expression of HIF-1α had changed significantly from 46.15% down to 21.15% （P〈0.05）. The expression of VEGF had changed significantly from 55.77% down to 30.77%（P〈0.05）. Before and after chemotherapy, the expressions of HIF-1α and VEGF were positive correlation（P〈0.05）. Before neoadjuvant chemotherapy, the chemosensitivity of HIF-1α positive expression and VEGF positive expression were worse than the chemosensitivity of HIF-1α negative expression and VEGF negative expression（P〈0.05）. Conclusion HIF-1α and VEGF can be used as a predictor of breast cancer chemosensitivity to help develop individualized chemotherapy.